Phase II study of XELOX as adjuvant chemotherapy for locally advanced rectal cancer
Phase 2
Recruiting
- Conditions
- ocally advanced rectal cancer
- Registration Number
- JPRN-UMIN000008429
- Lead Sponsor
- Chubu Clinical Oncology Group(CCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Multiple malignacies to be treated (2)Uncontrollable peptic ulcer disease (3)Serious complications (4)Previous history of severe drug-induced allergy (5)Severe neuropathy (6)With interstitial lung disease or pulmonary fibrosis (7)Pregnant (8)Prior chemotherapy with oxaliplatin or capecitabin (9)Disqualified by attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method